No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DK240517C27500
- 1.30
- +0.30+30.00%
15min DelayClose May 17 15:59 ET
1.30High1.20Low
1.20Open1.00Pre Close17 Volume17 Open Interest27.50Strike Price2.05KTurnover553.30%IV4.15%PremiumMay 17, 2024Expiry Date1.16Intrinsic Value100Multiplier0DDays to Expiry0.14Time Value100Contract SizeAmericanOptions Type0.6358Delta0.0859Gamma12.20Leverage Ratio-3.0337Theta0.0001Rho7.75Eff Leverage0.0030Vega
Intraday
- 5D
- 1D
News
Delek US To Go Ex-Dividend On May 16th, 2024 With 0.25 USD Dividend Per Share
May 15th - $Delek US(DK.US)$ is trading ex-dividend on May 16th, 2024. Shareholders of record on May 17th, 2024 will receive 0.25 USD dividend per share on May 24th, 2024. The ex-dividend date is
Delek US Is Maintained at Neutral by Piper Sandler
Delek US Is Maintained at Neutral by Piper Sandler
Express News | Piper Sandler Maintains Neutral on Delek US Hldgs, Lowers Price Target to $30
Analysts' Opinions Are Mixed on These Energy Stocks: Permian Resources (PR), Delek US Holdings (DK) and Energy Transfer (ET)
Delek US Is Maintained at Underperform by Mizuho
Delek US Is Maintained at Underperform by Mizuho
Express News | Delek US Holdings Inc : Mizuho Raises Target Price to $31 From $30
Comments
Delek US Holdings' low P/S ratio is due to predicted revenue decline. Investors see no significant potential for revenue growth to justify a higher P/S ratio. Without major changes, a significant stock price increase is unlikely. The company's weak outlook is pressuring the shares downwards.
Benign Growth For Delek US Holdings, Inc. (NYSE:DK) Underpins Its Share PriceThe board of Delek US Holdings expresses positive sentiment towards the appointment of Ms. Benson, highlighting her experience in risk management, capital markets, and green energies as instrumental for the company's strategic initiatives.
Delek's lower Return on Equity (ROE) coupled with high debt levels make it less attractive for investment. Investors should also consider profit growth rates and market expectations before investing in Delek or similar companies.
Gainers:
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
Read more